Primary Biliary Cholangitis

Slide 1 · Primary biliary cholangitis

Small intrahepatic bile duct autoimmunity

Pathogenesis • morphologic recognition • clinicopathologic diagnosis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Locate the biliary compartment targeted by PBC and explain its clinical consequences.

Explain proposed immune mechanisms and interpret the diagnostic value of AMA.

Recognize characteristic portal lesions, progressive ductopenia, and periportal cholestasis.

Apply the Robbins diagnostic framework and distinguish PBC from PSC.

Slide 3 · PBC is a small-duct autoimmune cholangiopathy

Inflammatory destruction targets small- and medium-sized intrahepatic bile ducts.

Large intrahepatic and extrahepatic bile ducts are generally not involved.

Continued bile duct injury causes cholestasis and secondary hepatocellular damage.

Duct compartment

Portal interlobular ducts

Larger intrahepatic ducts

Extrahepatic ducts

PBC target: Upper compartment

Slide 4 · Why the disease is no longer named “biliary cirrhosis”

Many patients are detected before advanced scarring develops.

Cirrhosis is a possible late consequence, not a prerequisite for diagnosis.

The term “primary biliary cholangitis” describes the characteristic inflammatory process.

Early cholangitis

Duct injury

Duct loss

Possible cirrhosis

Slide 5 · Anatomical orientation: Where the injury begins

The portal tract contains an interlobular bile duct beside vascular branches.

Inflammation is directed at duct epithelium within portal tracts.

A small-duct lesion may be present despite an unremarkable large-duct cholangiogram.

Small bile duct

Schematic — not a photomicrograph

Slide 6 · Sex distribution: Marked female predominance

Women account for roughly 90% of cases comparison.

The reported female-to-male ratio is approximately 9:1.

Sex predominance helps clinical suspicion but is not a diagnostic criterion.

Characteristic distribution

Women ~90%

Men ~10%

Descriptive values

Slide 7 · Age and geographical patterns

Peak incidence is described between 40 and 50 years.

The condition is more common in the United States and Northern Europe.

Relatively low incidence in Africa and the Indian subcontinent.

Clinical and pathological context

Integrate history, serology, laboratory profile, and morphology.

Slide 8 · Familial clustering indicates susceptibility

Relatives of affected patients have an increased risk of PBC.

Familial association supports inherited susceptibility rather than simple Mendelian transmission.

Genetic background is considered alongside possible environmental exposures.

Familial risk

Susceptible host

Potential immune injury

Conceptual mechanism

Slide 9 · Clinical spectrum: Early detection versus advanced disease

An asymptomatic patient may first be identified through an elevated alkaline phosphatase.

Symptomatic patients most often report fatigue and pruritus.

Jaundice, splenomegaly, and portal-hypertensive findings suggest later disease.

Biochemical detection

Symptoms

Cholestatic consequences

Advanced liver disease

Slide 10 · Where PBC fits within cholestatic liver disease

Cholestasis reflects impaired bile formation or flow with retention of biliary constituents.

PBC causes intrahepatic cholestasis through immune-mediated destruction of small ducts.

Large-duct obstruction and PSC can produce cholestasis through different anatomical lesions.

PBC: Small-duct destruction

Other mechanisms: Obstruction or large-duct sclerosis

Differential comparison

Slide 11 · Immune pathogenesis: An integrated model

Genetic susceptibility and proposed environmental triggers precede immune recognition.

Autoreactive T lymphocytes target bile duct epithelial cells.

Duct injury and loss impair bile drainage, causing cholestatic hepatocyte injury.

Susceptibility

Proposed trigger

T-cell duct injury

Cholestasis

Conceptual mechanism

Slide 12 · The initiating trigger remains unknown

Infectious exposures and toxic chemicals have been proposed as contributors.

A specific initiating exposure has not been established.

Avoid presenting a single infection or toxicant as the proven cause of PBC.

Established observation ≠ complete mechanism

Interpret proposed triggers and causal links with caution.

Slide 13 · The T-cell component of duct injury

PBC is considered a T-cell-mediated autoimmune disorder.

Lymphocytes infiltrate and damage the epithelium of small interlobular ducts.

PDC-E2-specific T cells support immune recognition of a mitochondrial autoantigen.

Small bile duct

Schematic — not a photomicrograph

Slide 14 · PDC-E2 defines the characteristic autoimmune target

PDC-E2 is the E2 subunit of the pyruvate dehydrogenase complex.

Antimitochondrial antibodies in PBC characteristically recognize this component.

Its antigenic recognition is diagnostically important, even though the full injury mechanism remains uncertain.

PDC-E2 antigen

AMA recognition

Diagnostic association

Conceptual mechanism

Slide 15 · AMA is a marker—not a measured injury severity scale

Antimitochondrial antibodies are highly characteristic of PBC.

AMA titers do not correlate reliably with disease severity or progression.

AMA titers also do not predict response to therapy.

Characteristic marker

Not a severity measure

Not a response predictor

Slide 16 · Why AMA cannot be assumed to cause duct destruction

A minority of otherwise typical patients have no detectable AMA.

PDC-E2-directed T cells provide independent evidence of cellular autoimmunity.

The causal role of the circulating autoantibody itself remains uncertain.

Established observation ≠ complete mechanism

Interpret proposed triggers and causal links with caution.

Slide 17 · Additional autoantibodies may accompany PBC

Autoantibodies against nuclear pore proteins are described.

Anticentromere and other antinuclear reactivities may also occur.

These findings supplement—not replace—the textbook’s standard diagnostic framework.

Clinical and pathological context

Integrate history, serology, laboratory profile, and morphology.

Slide 18 · Loss of bile ducts creates a cholestatic cascade

Immune destruction reduces effective bile duct drainage.

Retained bile salts and other biliary constituents injure adjacent liver parenchyma.

Chronic injury can produce ductular response, fibrosis, and eventually cirrhosis.

Duct destruction

Bile retention

Hepatocyte injury

Fibrosis

Conceptual mechanism

Slide 19 · Normal bile supports excretion and fat absorption

Bile carries bilirubin, cholesterol, and other solutes toward the intestine.

Bile acids help emulsify dietary fat to permit absorption.

PBC-related impairment can therefore affect both hepatic tissue and intestinal nutrient handling.

Hepatic bile production

Small ducts

Intestinal delivery

Fat absorption

Conceptual mechanism

Slide 20 · Laboratory cholestasis reflects disturbed biliary physiology

Canalicular and biliary epithelial injury is associated with elevated alkaline phosphatase.

Gamma-glutamyl transferase is another characteristic cholestatic enzyme.

A cholestatic enzyme pattern does not, by itself, establish PBC as the cause.

ALP elevation

GGT elevation

Cause still requires evaluation

Slide 21 · Morphologic sequence: Injury to duct loss

Early disease may involve only a subset of portal tracts.

The characteristic inflammatory duct lesion precedes progressive disappearance of small ducts.

Long-standing cholestasis creates secondary parenchymal changes and fibrosis.

Patchy duct injury

Florid lesion

Ductopenia

Chronic biliary scarring

Slide 22 · The diagnostic target is the interlobular bile duct

Small bile duct epithelium is directly damaged by inflammatory infiltrates.

The duct lumen and epithelial continuity may become difficult to recognize.

Portal inflammatory changes must be interpreted relative to an actual duct profile.

Small bile duct

Schematic — not a photomicrograph

Slide 23 · Florid duct lesion: Defining microscopic pattern

Lymphocytes infiltrate and injure a small interlobular bile duct.

Granulomatous inflammation may surround or center on the damaged duct.

The combination is highly characteristic of PBC when present.

Small bile duct

Schematic — not a photomicrograph

Slide 24 · Granulomas in PBC are often poorly formed

Epithelioid granulomas may be identified within portal tracts.

Some granulomatous reactions are centered specifically on damaged bile ducts.

A portal granuloma alone is not diagnostic without bile duct injury context.

Small bile duct

Schematic — not a photomicrograph

Slide 25 · Portal lymphoplasmacytic inflammation accompanies duct injury

Portal tracts commonly contain lymphocytes and plasma cells.

The inflammatory infiltrate may be extensive even when a florid lesion is focal.

Interpret inflammation alongside duct epithelial injury and loss.

Small bile duct

Schematic — not a photomicrograph

Slide 26 · Ductular reaction represents a response to injury

Ductular proliferation may be seen in inflamed portal regions.

It accompanies chronic disturbance of the small-duct compartment.

Ductular reaction alone is not specific for PBC.

Small-duct injury

Biliary response

Ductular reaction

Slide 27 · Patchiness makes a biopsy vulnerable to sampling error

Early injury often affects a minority of portal tracts.

A core may miss the most characteristic granulomatous duct lesion.

The absence of a florid lesion in one sample does not exclude PBC.

Patchy portal tract involvement

Schematic: Selected ducts injured; Sampling matters

Slide 28 · Portal tract sampling: Intact ducts versus injured ducts

Review multiple portal tracts rather than focusing on a single dramatic area.

Distinguish preserved ducts from actively injured ducts and absent ducts.

Link morphologic interpretation to biochemical and serologic findings.

Patchy portal tract involvement

Schematic: Selected ducts injured; Sampling matters

Slide 29 · Ductopenia emerges with disease progression

Progressive loss of intrahepatic small ducts is a major late morphologic change.

Duct loss worsens impaired bile drainage and supports chronic cholestasis.

Ductopenia occurs in other disorders, so its cause requires clinicopathologic correlation.

Inflamed duct

Damaged duct

Reduced duct profiles

Cholestasis

Slide 30 · PBC cholestasis tends to be periportal or periseptal

Bile accumulation in PBC is not typically centered in the centrilobular zone.

The source emphasizes periportal/periseptal distribution.

This localization can help distinguish patterns of cholestatic injury.

Schematic hepatic acinar axis

Portal region

Central zone

PBC: Periportal / periseptal

Compare other zonal patterns

Conceptual distribution; Not tissue scale

Slide 31 · Cholate stasis changes periportal hepatocytes

Bile salt retention produces swollen hepatocytes with pale cytoplasm.

Fine granular cytoplasmic strands produce the appearance termed feathery degeneration.

This reaction is associated with chronic biliary injury rather than exclusively with PBC.

Cholate-stasis hepatocyte

Schematic — not an H&E specimen

Slide 32 · Mallory hyaline may occur in chronic cholestatic injury

Periportal hepatocytes with cholate stasis may develop Mallory hyaline.

The inclusion is not unique to PBC or to alcoholic liver injury.

Its significance depends on the surrounding biliary pattern.

Cholate-stasis hepatocyte

Schematic — not an H&E specimen

Slide 33 · Cholate stasis is a pattern, not a specific diagnosis

Periportal feathery degeneration points to a chronic biliary process.

Similar hepatocellular changes can appear across chronic biliary disorders.

A diagnosis of PBC still depends on serology, clinical evidence, and duct-specific lesions.

Cholate stasis

Chronic biliary injury

Not PBC-specific

Slide 34 · Fibrosis and nodular regeneration are late consequences

Persistent cholestasis may culminate in cirrhosis.

Biliary cirrhotic nodules may be elongated or garland-shaped.

The textbook contrasts this pattern with rounder nodules in hepatitic cirrhosis.

Persistent injury

Fibrosis

Regenerative nodules

Cirrhosis

Slide 35 · Portal hypertension may develop without established cirrhosis

Some patients develop nodular regenerative hyperplasia.

This may produce portal hypertension despite the absence of conventional fibrotic cirrhosis.

The basis of nodular regenerative hyperplasia in PBC remains uncertain.

Established observation ≠ complete mechanism

Interpret proposed triggers and causal links with caution.

Slide 36 · Histology: What is characteristic and what is nonspecific?

Highly characteristic: Destructive lymphocytic/granulomatous small-duct lesion.

Supportive: Portal inflammation, ductular reaction, patchy duct loss.

Nonspecific chronic consequences: Feathery degeneration, fibrosis, regenerative change.

Florid lesion: Characteristic

Duct loss: Supportive

Cholate stasis: Nonspecific

Slide 37 · The textbook lesion in one conceptual view

Inflamed portal tract with destruction centered on a small bile duct.

Lymphocytes and plasma cells surround the duct; Granulomatous reaction may coexist.

This is the lesion described in the source’s Fig. 18.36—not a reproduced photomicrograph.

Small bile duct

Schematic — not a photomicrograph

Slide 38 · Fatigue and pruritus are the common symptomatic presentation

Both symptoms may develop insidiously and progress gradually.

They reflect a disease that may be biochemically apparent before advanced structural injury.

Symptom severity alone does not define the microscopic stage.

Clinical and pathological context

Integrate history, serology, laboratory profile, and morphology.

Slide 39 · Asymptomatic PBC is an important detection pathway

Increasing numbers of cases are identified by persistently elevated serum alkaline phosphatase.

Patients may have no jaundice or other obvious signs of advanced disease.

Serologic evaluation becomes important when a persistent cholestatic profile is detected.

Incidental ALP elevation

Persistent cholestatic profile

AMA assessment

PBC evaluation

Conceptual mechanism

Slide 40 · Pruritus is a cholestatic clinical clue

Pruritus is among the characteristic early symptoms.

It may occur before clinically evident jaundice.

Its presence should be considered alongside biochemical and autoimmune findings.

Clinical and pathological context

Integrate history, serology, laboratory profile, and morphology.

Slide 41 · Hypercholesterolemia and xanthelasma

Disturbed bile-related cholesterol handling is often accompanied by hypercholesterolemia.

Xanthelasmas can become a visible manifestation of lipid deposition.

Neither hypercholesterolemia nor xanthelasma alone establishes the diagnosis.

Cholestatic disease

Hypercholesterolemia

Possible xanthelasma

Conceptual mechanism

Slide 42 · Malabsorption reflects reduced effective bile delivery

Steatorrhea may accompany cholestasis as intestinal fat handling becomes impaired.

Failure of adequate fat emulsification can affect absorption of fat-soluble nutrients.

Such consequences become clinically relevant in sustained disease.

Reduced bile delivery

Impaired fat absorption

Steatorrhea

Conceptual mechanism

Slide 43 · Vitamin D deficiency links cholestasis to bone disease

Vitamin D malabsorption is described in PBC.

Osteomalacia and osteoporosis may follow impaired vitamin D and skeletal homeostasis.

Bone disease is part of the systemic clinical impact of chronic cholestasis.

Chronic cholestasis

Vitamin D malabsorption

Bone complications

Conceptual mechanism

Slide 44 · Progression produces additional systemic manifestations

Skin hyperpigmentation may be present.

Jaundice and splenomegaly are emphasized in more advanced disease.

These findings suggest progression beyond isolated biochemical cholestasis.

Biochemical cholestasis

Fatigue / pruritus

Systemic effects

Advanced features

Slide 45 · Autoimmune disease associations are diagnostically useful

Sjögren syndrome, thyroiditis, and systemic sclerosis are prominent associations.

Rheumatoid arthritis, Raynaud phenomenon, and celiac disease may coexist.

Associated autoimmunity increases clinical suspicion but is not a substitute for PBC criteria.

Sjögren / thyroiditis

Systemic sclerosis

Other autoimmune disorders

Slide 46 · PBC versus autoimmune hepatitis: Different primary targets

PBC centers on destruction of small interlobular bile ducts.

Autoimmune hepatitis centers on hepatocellular inflammation and interface injury.

Overlap is possible, so atypical biochemical and histologic patterns require broader consideration.

PBC: Bile duct injury

AIH: Hepatocyte/interface injury

Differential comparison

Slide 47 · First diagnostic clue: A persistent cholestatic enzyme pattern

Elevated alkaline phosphatase for more than 6 months is one textbook criterion.

A single abnormal result does not satisfy the stated persistence requirement.

The biochemical pattern establishes a cholestatic phenotype, not the etiology by itself.

ALP elevated

Persistence >6 months

Evaluate etiology

Slide 48 · Antimitochondrial antibodies provide strong serologic support

AMA is detected in approximately 90%–95% of patients.

It can be present at all stages of the disease.

Its high disease association makes it especially useful with persistent cholestatic enzymes.

Characteristic serology

AMA-positive ~90–95%

AMA-negative minority

Descriptive values

Slide 49 · AMA testing methods: Immunofluorescence versus ELISA

Indirect immunofluorescence can detect characteristic AMA reactivity.

PDC-E2-directed ELISA selectively detects the defined target antigen.

Higher sensitivity and specificity for its ELISA approach.

Indirect immunofluorescence

PDC-E2-specific ELISA

Differential comparison

Slide 50 · IgM elevation is a supportive—not defining—finding

Many patients have increased circulating IgM.

The biological basis of this elevation is not established in the source text.

IgM is not one of the three specified Robbins diagnostic criteria.

May be elevated

Mechanism uncertain

Not a core criterion

Slide 51 · Robbins diagnosis uses a two-of-three framework

Persistently elevated alkaline phosphatase for more than 6 months.

Positive antimitochondrial antibody test.

Characteristic liver histology showing bile duct injury.

Any two of these three support the textbook diagnosis.

Any two of three source criteria

ALP elevated >6 months

AMA positive

Characteristic histology

Robbins 11th-edition diagnostic framework

Slide 52 · Diagnostic combinations: Serology may obviate histologic proof

Persistent ALP elevation plus AMA positivity provides two criteria.

AMA plus characteristic histology can also reach two criteria.

Persistent ALP elevation plus characteristic histology supports AMA-negative disease.

Any two of three source criteria

ALP elevated >6 months

AMA positive

Characteristic histology

Robbins 11th-edition diagnostic framework

Slide 53 · AMA-negative PBC remains within the disease spectrum

A minority of typical patients lack detectable AMA.

The textbook labels some of these cases autoimmune cholangiopathy/cholangitis.

Clinical presentation, histology, and natural history are otherwise similar.

AMA-positive PBC

AMA-negative PBC

Differential comparison

Slide 54 · Morphology is especially useful when serology is negative

A characteristic florid duct lesion can support a difficult diagnosis.

Patchy portal involvement reduces biopsy sensitivity for the most specific lesion.

Chronic cholestatic injury alone should not be mistaken for diagnostic duct destruction.

Patchy portal tract involvement

Schematic: Selected ducts injured; Sampling matters

Slide 55 · Large-duct imaging is usually unremarkable in PBC

The primary injury is in small intrahepatic ducts rather than the major biliary tree.

Typically normal PBC radiology with PSC beading and strictures.

A normal large-duct study does not rule out PBC.

Duct compartment

Portal interlobular ducts

Larger intrahepatic ducts

Extrahepatic ducts

PBC target: Upper compartment

Slide 56 · Anatomical differential: PBC versus PSC

PBC: Small interlobular intrahepatic ducts, with florid inflammatory duct lesions.

PSC: Extrahepatic and large intrahepatic ducts, with fibrosis and strictures.

The anatomical difference explains why cholangiographic appearances diverge.

PBC: Small ducts

PSC: Large ducts

Differential comparison

Slide 57 · Epidemiology and associations help separate PBC from PSC

PBC: Approximately 90% female; Median age near 50 years table.

PSC: Approximately 70% male; Median age near 30 years in the table.

Sjögren/thyroid disease suggests PBC; Inflammatory bowel disease suggests PSC.

PBC: Female / autoimmune associations

PSC: Male / inflammatory bowel disease

Differential comparison

Slide 58 · Serology differentiates—but does not perfectly classify

PBC is typically AMA positive, whereas PSC is usually AMA negative.

PBC can show ANA; PSC may show antineutrophil cytoplasmic antibodies.

Interpret panels in the context of duct anatomy and imaging.

PBC: Characteristic AMA

PSC: ANCA association

Differential comparison

Slide 59 · Histologic contrast: Florid lesion versus onion-skin scar

PBC: Lymphocytic or granulomatous destruction of small interlobular ducts.

PSC: Dense concentric fibrosis may entrap or obliterate a duct.

Neither single lesion should be used without clinicopathologic correlation.

PBC: Florid duct lesion

PSC: Concentric periductal fibrosis

Differential comparison

Slide 60 · Other cholestatic diseases can mimic individual findings

Large-duct obstruction alters bile flow through a mechanical process.

Drug-associated and sepsis-associated cholestasis may show different zonal patterns.

The combination of duct-centered inflammation, AMA, and clinical context is more discriminating.

Schematic hepatic acinar axis

Portal region

Central zone

PBC: Periportal / periseptal

Compare other zonal patterns

Conceptual distribution; Not tissue scale

Slide 61 · Long-term course: Slow but potentially progressive

PBC as generally slowly progressive.

End-stage liver disease occurs in approximately 20%–25% over 15–20 years description.

These population estimates are not individualized predictions.

Early disease

Persistent cholestasis

Fibrosis

Possible end stage

Slide 62 · Ursodeoxycholic acid modifies progression

Oral ursodeoxycholic acid is described as the principal disease-modifying therapy.

It slows disease progression in most affected patients.

Inadequate response in up to 40%, requiring specialist reassessment.

PBC diagnosis

UDCA treatment

Assess response

Reevaluate nonresponse

Conceptual mechanism

Slide 63 · Advanced disease may require liver transplantation

Transplantation is an established option for end-stage disease.

Survival exceeding 70% at 7 years after transplantation.

This historical source estimate should not be substituted for current center-specific outcomes.

Progressive damage

End-stage disease

Transplantation

Slide 64 · Hepatocellular carcinoma remains a relevant long-term risk

As with other chronic hepatic injury, PBC increases the risk of hepatocellular carcinoma.

Risk assessment should consider the extent and chronicity of liver disease.

Clinical surveillance policy is beyond the source-based pathology teaching scope.

Clinical and pathological context

Integrate history, serology, laboratory profile, and morphology.

Slide 65 · Case A: Biochemical presentation without symptoms

A middle-aged woman is asymptomatic but has persistently increased alkaline phosphatase.

AMA testing is positive; Large-duct imaging is unrevealing.

Which disease mechanism explains this pattern, and which criteria are met?

Interpret the pattern

Anatomy → laboratory profile → serology → morphology

Slide 66 · Case A: Apply the source-based criteria

The phenotype suggests autoimmune injury of small intrahepatic bile ducts.

Persistent ALP elevation and AMA positivity fulfill two textbook criteria.

A florid duct lesion would be characteristic but is not necessary to form the two-item combination.

Any two of three source criteria

ALP elevated >6 months

AMA positive

Characteristic histology

Robbins 11th-edition diagnostic framework

Slide 67 · Case B: Cholestasis with negative AMA

A patient has persistent cholestatic enzymes but AMA is not detected.

A biopsy shows patchy destructive lymphocytic inflammation centered on small bile ducts.

What diagnosis remains possible, and what is the role of sampling?

Interpret the pattern

Anatomy → laboratory profile → serology → morphology

Slide 68 · Case B: Interpret seronegative destructive cholangitis

AMA-negative PBC remains possible because typical cases can lack AMA.

Biochemical persistence plus characteristic bile duct histology fulfill the textbook framework.

Patchiness means a negative core result would require cautious interpretation.

Patchy portal tract involvement

Schematic: Selected ducts injured; Sampling matters

Slide 69 · Case C: When PBC is unlikely to explain the image

A patient with inflammatory bowel disease has cholestasis and biliary strictures.

Imaging shows alternating strictures and dilatations of large bile ducts.

Which alternative cholangiopathy better explains the duct distribution?

Interpret the pattern

Anatomy → laboratory profile → serology → morphology

Slide 70 · Case C: Recognize a PSC-pattern process

Large-duct beading and strictures favor PSC over the typical small-duct pattern of PBC.

Inflammatory bowel disease is a strong clinical association of PSC.

Concentric ductal scarring contrasts with the florid duct lesion of PBC.

PBC: Small ducts / normal imaging

PSC: Strictures / beading

Differential comparison

Slide 71 · Integrated diagnostic and morphologic synthesis

Clinical context: Middle-aged patient, often female, with fatigue/pruritus or incidental ALP elevation.

Serology: AMA, especially PDC-E2-directed, is strongly characteristic but not universal.

Histology: Patchy destructive small-duct inflammation with possible granulomas; Later ductopenia and cholate stasis.

Outcome: Fibrosis, cirrhosis or noncirrhotic portal hypertension may develop.

Small-duct attack

Florid duct lesion

AMA / PDC-E2

Chronic cholestasis

Slide 72 · Core references and source boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026), Chapter 18, pp. 775–782.

PBC source section: pp. 780–781; companion sections: Cholestatic Disease and Primary Sclerosing Cholangitis.

All histologic depictions in this lecture are original editable schematics—not patient photomicrographs.

Treatment descriptions reproduce the textbook-level framework; current regulatory details were not independently verified.